ClearPoint Neuro, Inc. $CLPT Shares Bought by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. increased its stake in ClearPoint Neuro by 98.3% in Q1, owning approximately 257,871 shares worth $3.07 million.
• ClearPoint Neuro's stock has seen a decline of 1.3% recently, with a current price of $11.20, while it holds a market cap of $318.42 million and a negative PE ratio of -13.83.
• Analysts currently rate ClearPoint Neuro with a consensus "Buy" and a target price of $19.67, reflecting a potential upside from its recent trading price.

Goldman Sachs Group Inc. lifted its holdings in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 98.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 257,871 shares of the company's stock after acquiring an additional 127,823 shares during the period. Goldman Sachs Group Inc. owned 0.92% of ClearPoint Neuro worth $3,066,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Deutsche Bank AG acquired a new stake in ClearPoint Neuro in the first quarter valued at about $63,000. Cannon Global Investment Management LLC acquired a new position in ClearPoint Neuro in the 1st quarter valued at $143,000. State of Wyoming acquired a new stake in shares of ClearPoint Neuro in the fourth quarter worth approximately $145,000. Two Sigma Investments LP acquired a new stake in ClearPoint Neuro during the 4th quarter worth approximately $159,000. Finally, Dauntless Investment Group LLC acquired a new stake in ClearPoint Neuro during the 1st quarter worth approximately $166,000. Institutional investors and hedge funds own 30.08% of the company's stock.

Analyst Ratings Changes

CLPT has been the subject of a number of recent analyst reports. Stifel Nicolaus raised their price objective on ClearPoint Neuro from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Wall Street Zen upgraded shares of ClearPoint Neuro from a "sell" rating to a "hold" rating in a research note on Saturday, September 13th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $19.67.

ClearPoint Neuro Stock Performance

Shares of NASDAQ:CLPT traded up $0.94 during mid-day trading on Monday, reaching $12.14. The company had a trading volume of 323,821 shares, compared to its average volume of 313,916. The company's 50-day moving average price is $10.86 and its 200-day moving average price is $11.93. The firm has a market cap of $344.96 million, a price-to-earnings ratio of -15.01 and a beta of 0.89. ClearPoint Neuro, Inc. has a one year low of $9.76 and a one year high of $19.22. The company has a current ratio of 7.30, a quick ratio of 6.45 and a debt-to-equity ratio of 1.46.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). ClearPoint Neuro had a negative net margin of 66.15% and a negative return on equity of 94.44%. The company had revenue of $9.22 million for the quarter, compared to the consensus estimate of $9.20 million. ClearPoint Neuro has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 EPS for the current fiscal year.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.